Spectrum expands Phase ll trial of poziotinib for NSCLC
Spectrum Pharmaceuticals has expanded its Phase ll clinical trial of poziotinib for the treatment of non-small cell lung cancer (NSCLC)…
NSCLC Spectrum Pharmaceuticals poziotinib
Spectrum expands Phase ll trial of poziotinib for NSCLC
Spectrum Pharmaceuticals has expanded its Phase ll clinical trial of poziotinib for non-small cell lung cancer (NSCLC) by adding two…